We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Panel Predicts Likely Survival Time for Ovarian Cancer Patients

By LabMedica International staff writers
Posted on 25 Aug 2020
Print article
Image: Formalin-Fixed Paraffin-Embedded (FFPE) blocks containing ovarian cancer samples (Photo courtesy of  University of New South Wales)
Image: Formalin-Fixed Paraffin-Embedded (FFPE) blocks containing ovarian cancer samples (Photo courtesy of University of New South Wales)
A large international consortium of ovarian cancer researchers identified a panel of genes that could identify patients who were least likely to achieve five-year survival.

Ovarian cancer is the eighth most commonly occurring cancer in women, with nearly 300,000 new cases reported worldwide in 2018. Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is approximately four years, yet survival varies widely between patients, and there are no well-established gene expression signatures associated with prognosis.

Investigators at the University of New South Wales (Sydney, Australia) together with colleagues from 86 Australian and foreign research institutions initiated a project to develop a robust prognostic genetic signature for OS in patients with HGSOC.

Tissue samples for this study were provided by the Ovarian Tumor Tissue Analysis (OTTA) consortium. The investigators analyzed the expression of 513 genes, selected from a meta-analysis of 1455 tumors and other candidates, using NanoString technology from formalin-fixed paraffin-embedded (FFPE) tumor tissue collected from 3769 women with HGSOC from multiple studies. NanoString technology, which is a variation of DNA microarray, uses molecular "barcodes" and microscopic imaging to detect and count up to several hundred unique transcripts in one hybridization reaction.

Results revealed that expression levels of 276 genes were associated with OS (false discovery rate less than 0.05). The top five genes were TAP1 (Transporter associated with Antigen Processing 1), ZFHX4 (Zinc Finger Homeobox 4), CXCL9 (C-X-C motif chemokine ligand 9), FBN1 (Fibrillin 1) and PTGER3 (Prostaglandin E Receptor 3). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications.

"We conducted an analysis of 3,769 tumor samples from women with ovarian cancer and found we were able to reliably use a piece of tumor to determine how good a woman's survival chances would be five years after diagnosis," said senior author Dr. Susan Ramus, head of the molecular oncology group at the University of New South Wales. "When women were divided into five groups, we found that the women whose tumor gene expression was associated with the best prognosis had nine years survival, whereas the women in the poorest survival group have two years survival, which is a very big difference. Our vision is that clinicians could use our test at diagnosis to identify the group of patients who would not do well on the current treatments and potentially offer them alternatives - for example, we may be able to put those patients into clinical trials and offer them different treatments that may improve their survival."

The ovarian cancer study was published in the May 27, 2020, online edition of the journal Annals of Oncology.

Related Links:
University of New South Wales

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.